title: Ondansetron versus metoclopramide in the treatment of postoperative nausea and vomiting.
abstract: In this prospective, randomized, double-blind study, we compared the efficacy and safety of ondansetron and metoclopramide in the treatment of postoperative nausea and vomiting (PONV). One hundred seventy-five patients with PONV during recovery from anesthesia for gynecological laparoscopy were treated intravenously with either ondansetron 4 mg (58 patients), metoclopramide 10 mg (57 patients), or placebo (60 patients). Early antiemetic efficacy (abolition of vomiting within 10 min and of nausea within 30 min from the administration of the study drugs with no further vomiting or nausea episodes during the first hour) was obtained in 54 of 58 patients (93.1%) in the ondansetron group, in 38 of 57 patients (66.7%) in the metoclopramide group, and in 21 of 60 patients (35%) in the placebo group (P < 0.001). This difference was still significant when controlling for age, body weight, history of motion sickness, previous PONV episodes, duration of anesthesia, and intraoperative fentanyl consumption using a logistic model. Early antiemetic efficacy was inversely related to the amount of fentanyl administered during anesthesia, regardless of treatment. According to the Kaplan-Meier method, the probability of remaining PONV-free for 48 h after a successful treatment was 0.59 (95% confidence interval 0.45-0.71) in the ondansetron group, 0.45 (0.29-0.60) in the metoclopramide group, and 0.33 (0.15-0.53) in the placebo group (P = 0.003). In conclusion, ondansetron 4 mg is more effective than metoclopramide 10 mg and placebo in the treatment of established PONV.
authors.affiliation: Institute of Anesthesiology and Intensive Care, University of Verona, Italy.
authors.forename: E
authors.initials: E
authors.lastname: Polati
authors.forename: G
authors.initials: G
authors.lastname: Verlato
authors.forename: G
authors.initials: G
authors.lastname: Finco
authors.forename: W
authors.initials: W
authors.lastname: Mosaner
authors.forename: S
authors.initials: S
authors.lastname: Grosso
authors.forename: L
authors.initials: L
authors.lastname: Gottin
authors.forename: A M
authors.initials: AM
authors.lastname: Pinaroli
authors.forename: S
authors.initials: S
authors.lastname: Ischia
mesh_terms: D000293:Adolescent; D000328:Adult; D000367:Age Factors; D000368:Aged; D000762:Anesthesia Recovery Period; D018686:Anesthetics, Intravenous / Q000008:administration & dosage; D000932:Antiemetics / Q000008:administration & dosage / Q000627:therapeutic use*; D001835:Body Weight; D016001:Confidence Intervals; D004311:Double-Blind Method; D005260:Female; D005283:Fentanyl / Q000008:administration & dosage; D005836:Genitalia, Female / Q000601:surgery; D006801:Humans; D007275:Injections, Intravenous; D010535:Laparoscopy; D016015:Logistic Models; D008787:Metoclopramide / Q000008:administration & dosage / Q000627:therapeutic use*; D008875:Middle Aged; D009041:Motion Sickness / Q000503:physiopathology; D009325:Nausea / Q000188:drug therapy*; D017294:Ondansetron / Q000008:administration & dosage / Q000627:therapeutic use*; D010919:Placebos; D011183:Postoperative Complications / Q000188:drug therapy*; D011336:Probability; D011446:Prospective Studies; D012449:Safety; D013997:Time Factors; D014839:Vomiting / Q000188:drug therapy*
chemical_list: D018686:Anesthetics, Intravenous; D000932:Antiemetics; D010919:Placebos; D017294:Ondansetron; D008787:Metoclopramide; D005283:Fentanyl